Supporting your patients with HAE on ANDEMBRY® (garadacimab) or BERINERT® (C1-esterase inhibitor, human)
Supporting your patients with HAE on ANDEMBRY® (garadacimab) or BERINERT® (C1-esterase inhibitor, human)
With our downloadable resources and tools, you can support your patients to understand and manage their treatment.
ANDEMBRY® (garadacimab) is indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in adult and adolescent patients aged 12 years and older.1
BERINERT® (C1-esterase inhibitor, human) for subcutaneous injection is indicated for prevention of recurrent hereditary angioedema (HAE) attacks in adolescent and adult patients with C1-esterase inhibitor deficiency.2,3
Featured content
Featured content
HAE EXPERT HUB
A guide to ANDEMBRY® treatment
Support your patients' understanding of HAE and ANDEMBRY® with this guide which covers:
- What is HAE?
- How ANDEMBRY® works
- Key safety information
- How to administer ANDEMBRY®
More resources
More resources
BERINERT® SC
administration guide
Give your patients a practical and accessible guide designed to remind them on how to administer subcutaneous BERINERT® 2000 IU and 3000 IU. This resource contains detailed, step-by-step instructions on how to inject their medicine.
Order ANDEMBRY®
demonstration pens
With demo pens, you can show your patients how to use and administer their medication in your clinical practice. If you’re interested in ANDEMBRY® demo pens, please get in touch using the email below.
Order your copy of the
VANGUARD clinical paper
Get your copy of the pivotal phase 3 clinical trial that supported licensing and NICE approval of ANDEMBRY®. If you want to review the VANGUARD efficacy and safety data, get in touch with your local representative using the email below.
Explore More
Explore More
Discover the latest insights on ANDEMBRY®
Hear HAE experts discuss clinical evidence for ANDEMBRY® and share real-world patient case studies.
Learn how ANDEMBRY® is changing the path in HAE
Review key clinical data and the mechanism of action for ANDEMBRY®.
Explore HAE attack reduction with ANDEMBRY® (VANGUARD)
Review key efficacy data from pivotal phase 3 VANGUARD trial for ANDEMBRY®.
Abbreviations: HAE, hereditary angioedema; NICE, National Institute for Health and Care Excellence; SC, subcutaneous.
References:
1. ANDEMBRY® (garadacimab). Summary of Product Characteristics.
2. BERINERT® 2000 IU (C1-esterase inhibitor, human). Summary of Product Characteristics.
3. BERINERT® 3000 IU (C1-esterase inhibitor, human). Summary of Product Characteristics.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple store. Adverse events should also be reported to CSL Behring UK Ltd. on 01444 447405.
GBR-AND-0315 | May 2026.